Phibro Animal Health (PAHC) vs Stoke Therapeutics (STOK)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Phibro Animal Health (PAHC) has outperformed Stoke Therapeutics (STOK) over the past year, gaining 0.8% versus a loss of 21.5%. Over five years, PAHC leads with a +71.6% price change compared with +1.8% for STOK. Stoke Therapeutics is the larger company by market cap ($1.55 billion vs $1.52 billion), about 1.0 times the size.
Phibro Animal Health pays a dividend yielding 1.28%, while Stoke Therapeutics does not currently pay one. Phibro Animal Health converts more of its revenue into profit, with a net margin of 6.6% versus -3.7%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PAHC | STOK |
|---|---|---|
| Share price | $37.40 | $23.95 |
| Market cap | $1.52B | $1.55B |
| 1-day change | -0.85% | -1.40% |
| YTD return | +0.11% | -24.54% |
| 1-year return | +0.78% | -21.48% |
| 5-year return | +71.56% | +1.83% |
| P/E ratio (TTM) | 15.39 | — |
| Forward P/E | 9.73 | — |
| EPS (TTM) | $2.43 | $-3.38 |
| Dividend yield | 1.28% | 0.00% |
| Annual dividend | $0.48 | $0.00 |
| Revenue (latest FY) | $1.52B | $184.42M |
| Revenue growth (YoY) | +17.12% | +404.50% |
| Net income (latest FY) | $99.72M | $-6.88M |
| Gross margin | 33.76% | — |
| Operating margin | 12.81% | -11.16% |
| Net margin | 6.57% | -3.73% |
| 52-week high | $60.08 | $40.22 |
| 52-week low | $28.25 | $20.32 |
| Distance from 52-week high | -37.75% | -40.45% |
| Analyst consensus | hold | strong_buy |
| Avg. price target upside | +17.65% | +93.99% |
| Average volume | 236.19K | 855.13K |
| Shares outstanding | 21.11M | 64.53M |
| Employees | 2,605 | 170 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PAHC has outperformed STOK by 22.3 percentage points over the past year.
- Phibro Animal Health offers a meaningfully higher dividend yield (1.28% vs 0.00%).
- Phibro Animal Health is more profitable, keeping 6.6 cents of every revenue dollar as net income versus -3.7 cents for Stoke Therapeutics.
- Stoke Therapeutics grew revenue faster in its latest fiscal year (+404.50% vs +17.12%).
About Phibro Animal Health
PAHC stock →Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Latin America and Canada, Europe, the Middle East, Africa, and the Asia Pacific. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products.
Health Care · Biotechnology: Pharmaceutical Preparations · 2,605 employees
About Stoke Therapeutics
STOK stock →Stoke Therapeutics, Inc. engages in the development of treatments for severe genetic diseases by upregulating protein expression.
Health Care · Biotechnology: Pharmaceutical Preparations · 170 employees
PAHC vs STOK FAQ
Which is bigger, Phibro Animal Health or Stoke Therapeutics?
Stoke Therapeutics (STOK) is larger, with a market capitalization of $1.55B compared with $1.52B for Phibro Animal Health (PAHC).
Which stock has performed better over the past year, PAHC or STOK?
PAHC returned +0.78% over the past 12 months, compared with -21.48% for STOK (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, Phibro Animal Health or Stoke Therapeutics?
Phibro Animal Health pays a dividend yielding 1.28%, while Stoke Therapeutics does not currently pay a regular dividend.
Are Phibro Animal Health and Stoke Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.